fda glp 1 compounding New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Today, the FDA is announcing
Description
Confirm current availability, pricing, and program terms for either program directly at galaglp1.com before completing any intake

6 For plan sponsors, the arrival of oral options means usage could grow, reinforcing the need for comprehensive utilization-management strategies

It operates as a glucagon-like peptide-1 receptor agonist, mimicking the effects of the GLP-1 hormone in your body

doi: 10.1210/jc.2002-021545

Weight regain after discontinuation Within a year of stopping GLP-1 therapy, 49% of patients were heavier than when they started (Abdel-Bary et al

Paulescu published his results the following year and then took out a Romanian patent on his technique in April 1922
